Bigger company and more $$$ means more demands and less profits in many cases. You'd also run a higher risk of having trials shut down if there's a problem, whereas a smaller partner wouldn't pull so much weight.
This is a great deal because the way I'm reading into it, they'd only have to share profits on South American and Caribbean markets. ROW, including the US and elsewhere aren't included in the agreement.
With a market cap just under 2B, I think that the expectations of approval are for the most part baked into the stock price. While there's always room for more upside movement, one also must take into consideration the risks of dealing with the FDA.